iRadimed Corporation
IRMD
Positions held
Your positionsIRMD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- iRadimed Corporation operates in the growing medical devices sector, which is expected to expand due to increasing healthcare demands and technological advancements.
- In Q2 2026, iRadimed reported a gross margin of 74.1%, demonstrating strong profitability despite recent revenue fluctuations.
- The company has a robust current ratio of 9.463, indicating excellent short-term financial health.
- The company's earnings growth has declined by 9.3%, raising concerns about its ability to maintain profitability in a competitive market.
- Revenue decreased by 7% in Q2 2026 compared to the previous quarter, signaling potential challenges in sustaining sales momentum.
- iRadimed's stock has a trailing P/E ratio of 47.39, suggesting it may be overvalued relative to its earnings growth prospects.
Fundamentals
| Market cap | $1.10B | Enterprise value | $1.04B | Trailing P/E | 47.98 | Forward P/E | 35.01 |
| PEG | — | Price / book | 10.79 | Beta | 0.91 | Dividend yield | 0.93% |
| Revenue growth | 0.3% | Earnings growth | -9.3% | Gross margin | 75.9% | Operating margin | 31.2% |
| Profit margin | 26.7% | ROE | 23.5% | ROA | 15.6% | Debt / equity | — |
| Current ratio | 9.46 | Free cash flow | $16.20M | Analyst recommendation | none | Mean target | $118.00 |
| 52w high | $107.90 | 52w low | $71.34 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $20.5M | $22.0M | $22.7M | $21.2M | $20.4M | — |
| Op margin | 31.2% | 32.9% | 31.3% | 32.2% | 33.3% | — |
| Net income | $5.2M | $5.8M | $6.4M | $5.6M | $5.8M | — |
| Gross margin | 74.1% | 76.5% | 75.1% | 77.8% | 78.2% | — |
| Gross profit | $15.2M | $16.8M | $17.0M | $16.5M | $16.0M | — |
| Operating income | $6.4M | $7.2M | $7.1M | $6.8M | $6.8M | — |
- Revenue -7% vs prior quarter ($20M vs $22M).
- Gross margin 74.1% (was 76.5% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | — |
| Op margin | 31.2% | 30.0% | 30.6% | 29.3% | — |
| Net income | $22.5M | $19.2M | $17.2M | $12.8M | — |
| Gross margin | 76.7% | 76.9% | 76.5% | 77.4% | — |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | — |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | — |
Headlines — positive tone
• [OK · fundamentals] iRadimed Corp (IRMD) (Q2 2026) Earnings Call Highlights: Strong Demand for New 3,870 Pump ...
News
2026-09-23 · IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
2026-09-21 · Market Strategist Julie Biel: The AI Craze Is Making These Quality Stocks More Affordable
2026-08-08 · IRadimed (IRMD) Q2 2026 Earnings Call Transcript
2026-08-07 · How IRADIMED's Modest Q2 Beat and Reaffirmed 2026 Guidance Will Impact IRMD Investors
2026-08-07 · Replacement Cycle Anchors IRadimed Corp.’s (IRMD) Long Term Growth
2026-08-04 · iRadimed Corp (IRMD) (Q2 2026) Earnings Call Highlights: Strong Demand for New 3,870 Pump ...
2026-08-01 · IRadimed Corporation Q2 2026 Earnings Call Summary
2026-07-31 · iRadimed Q2 Earnings Call Highlights
2026-07-31 · IRadimed Q2 Adjusted Earnings Fall, Revenue Rises; Issues Q3 Outlook, Reaffirms 2026 Guidance
2026-07-31 · IRadimed: Q2 Earnings Snapshot
2026-07-31 · IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
2026-07-27 · Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
Price (daily)
Full chart · RSI · MACD · patterns